Cyclic receptor-associated protein (RAP) peptides
View Patent ↗The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
1. A cyclic receptor associated protein (RAP) peptide that is less than or about 85 amino acids in length, comprising 50 contiguous amino acids that are at least 70% identical to SEQ ID NO: 97, and which binds to a complement repeat (CR)-containing protein with a binding affinity Kd of about 1×10 −8 M or less.
2. The cyclic RAP peptide of claim 1 that binds to lipoprotein receptor 1 (LRP1) with a Kd of about 1×10 −8 M or less.
3. The cyclic RAP peptide of claim 1 comprising a mutation at any one of positions 251, 256, 257, 266, 270, 279, 280, 296 or 305 of mature RAP set out in SEQ ID NO: 95.
4. The cyclic RAP peptide of claim 3 that contains at least one additional mutation within positions 271-319 of mature RAP set out in SEQ ID NO: 95.
5. The cyclic RAP peptide according to claim 3 , wherein said mutation is the replacement of an acidic amino acid with a basic amino acid.
6. The cyclic RAP peptide according to claim 3 , wherein said mutation is the replacement of a basic amino acid with an acidic amino acid.
7. The cyclic RAP peptide according to claim 3 , wherein said mutation is the replacement of an amino acid selected from the group consisting of A, C, D, E, G, I, K, L, M, N, P, Q, R, S, T, and V with an amino acid selected from the group consisting of F, Y, W, and H.
8. The cyclic RAP peptide of claim 1 that binds selectively to matriptase.
9. The cyclic RAP peptide of claim 8 comprising a mutation at any one of positions 251, 256, 257, 266, 270, or 280 of mature RAP set out in SEQ ID NO: 95.
10. The cyclic RAP peptide of claim 1 that binds selectively to a very low density lipoprotein receptor (VLDLR) protein.
11. The cyclic RAP peptide of claim 10 which comprises a mutation at any one of positions 251, 256, 270 or 296 of mature RAP set out in SEQ ID NO: 95.
12. The cyclic RAP peptide of claim 1 that binds selectively to an FDC-8D6 (CD320) protein.
13. The cyclic RAP peptide of claim 12 which comprises a mutation at any one of positions 251, 256, 270, 279 or 305 of mature RAP set out in SEQ ID NO: 95.
14. The cyclic RAP peptide of claim 1 that comprises SEQ ID NO: 97.
15. The cyclic RAP peptide of claim 1 that contains at least one mutation within positions 205-250 of mature RAP set out in SEQ ID NO: 95.
16. The cyclic RAP peptide of claim 1 that comprises a mutation at three or more of the following positions: 213, 217, 226, 230, 232, 239, 241, 242, 246, 247, 249, 250, 251, 256, 257, 261, 266, 267, 268, 270, 273, 279, 280, 287, 290, 294, 296, 297, 298, 305, 308, 311, 312, 313, 314, or 315 of mature RAP set out in SEQ ID NO: 95.
17. The cyclic RAP peptide of claim 1 that comprises a mutation at three or more of the following positions: 217, 249, 251, 256, 257, 266, 270, 294, 296, 297, 305 of mature RAP set out in SEQ ID NO: 95.
18. The cyclic RAP peptide of claim 1 that comprises three or more of the following mutations: S213T, E217K, L226M, H249Y, A230V, S232P, E239G, E246G, E251L, E251K, E251T, E251G, E251P, E251N, E251R, K256R, K256V, K256A, K256I, K256P, K256L, I266F, I266T, H257Y, Q261R, A267V, H268R, K270P, K270D, K270N, K270G, K270E, K270W, L271M, H273Y, D279Y, V283M, R287H, H290Y, H290L, E294V, R296L, T297I, K298R, K305T, K306M, S312F, G313D, E246C, L247G, G280A, L311A, S312C, Q309C, F250C, L308G, L311G, E241C, and I315C of mature RAP set out in SEQ ID NO: 95.
19. A pharmaceutical composition comprising a cyclic RAP peptide of claim 1 in a pharmaceutically acceptable carrier, diluent or excipient.
20. The cyclic RAP peptide of claim 1 , wherein the peptide comprises a RAP peptide having the following mutations, H249Y, E251K, K256A and K270E of mature RAP set out in SEQ ID NO: 95.